<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of acute pain in adults with opioid use disorder</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of acute pain in adults with opioid use disorder</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of acute pain in adults with opioid use disorder</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel Carr, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott Fishman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew J Saxon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marianna Crowley, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3886119036"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Opioid use disorder (OUD) has reached epidemic proportions in the United States. Patients with OUD commonly experience episodes of acute pain related to injury, illness, or surgery. This topic will discuss strategies for acute pain management in patients on medication-assisted treatment for OUD, eg, with <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, or <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a>, and pain management for patients with untreated OUD.</p><p>Management of acute pain in patients who are chronically using opioids for pain and management of acute pain in opioid naïve patients are discussed separately. (See  <a class="medical medical_review" href="/d/html/130312.html" rel="external">"Approach to the management of acute pain in adults"</a> and  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain"</a>.)</p><p class="headingAnchor" id="H23075561"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>The general principles of acute pain management in patients who take opioids chronically are discussed separately. These include challenges specific to these patients, evaluation of pain and baseline opioid use, and creation of a plan for treatment based on the expected degree and duration of pain. (See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain"</a>.)</p><p class="headingAnchor" id="H2646992265"><span class="h1">PATIENTS RECEIVING PHARMACOTHERAPY FOR OPIOID USE DISORDER</span><span class="headingEndMark"> — </span>Acute pain management in patients receiving medication-assisted treatment for OUD often requires coordination with substance use disorder treatment specialists, particularly if supplemental opioids are required [<a href="#rid1">1</a>].</p><p>The only opioid agonists approved for the treatment of OUD in the United States are <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> and <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>. Though each drug is often dosed once daily for addiction, their analgesic effects last only six to eight hours. Therefore, continuation of once-daily outpatient dosing for OUD alone is not sufficient for acute pain management. (See  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Methadone: Opioid agonist'</a> and  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Buprenorphine: Opioid agonist'</a>.)</p><p>The opioid antagonist <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> is also approved for maintenance treatment of OUD, as well as for treatment of alcohol use disorder. Naltrexone can be administered as a daily oral dose, or as a monthly intramuscular injection (see  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Naltrexone: Opioid antagonist'</a>). Management of acute pain in patients who take naltrexone poses distinctive challenges, as naltrexone blocks the effects of opioid agonists.</p><p class="headingAnchor" id="H1466851997"><span class="h1">PATIENTS ON METHADONE MAINTENANCE THERAPY</span><span class="headingEndMark"> — </span>The general approach to acute pain management in patients who take <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> is similar to the approach used for patients who take stable doses of other opioids on a chronic basis: continuation of the baseline opioid and dose and use of multimodal nonopioid analgesic strategies supplemented with incremental opioid if necessary during the interval of acute pain. Once acute pain subsides, the additional opioid is then tapered.</p><p>The plan for pain control should be based on the degree of existing or expected pain (eg, after elective surgery). The plan must be flexible because pain intensity and the requirement for additional opioid may be unpredictable in patients who chronically use opioids and often fluctuate with activity. The expected degree and duration of acutely painful events are discussed separately. (See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Creating a plan for treatment'</a>.)</p><p>Pain may be more difficult to control in patients who receive <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance therapy (MMT). Because opioid cross-tolerance may be present in patients who take methadone [<a href="#rid2">2-4</a>], patients on MMT typically require higher doses of opioid than opioid naïve patients. As an example, in a retrospective case control study of patients on MMT who underwent total knee arthroplasty, patients on MMT had higher median daily postoperative opioid use, higher patient-controlled analgesia (PCA) use, more inpatient pain management referrals, and longer hospital length of stay [<a href="#rid5">5</a>]. Similarly, a retrospective study of patients on MMT or <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> maintenance therapy (BMT) undergoing total knee arthroplasty found that patients in the MMT/BMT group required sevenfold greater doses of opioids in the perioperative period than opioid naive patients (793 milligram <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> equivalents [MME]/24 hours versus 109 MME/24 hours) [<a href="#rid6">6</a>]. One study of postpartum pain control found that patients on MMT required 70 percent higher opioid doses for analgesia after cesarean delivery than opioid naïve patients [<a href="#rid7">7</a>].</p><p>It is common for severe acute pain to be inadequately controlled in the hospital and postoperative settings among patients on MMT because supplemental doses of opioids are too low, or the doses are not titrated rapidly enough [<a href="#rid8">8,9</a>]. Additional opioids for acute pain should not be withheld for fear of worsening the OUD. As long as medications for acute pain are tapered promptly as the pain resolves, the patient's course of treatment for OUD can continue undisrupted.</p><p>To date, there are no trials of specific treatment protocols to guide management of acute pain in patients receiving MMT, and recommendations are based on expert opinion and retrospective clinical experience [<a href="#rid10">10-12</a>].</p><p class="headingAnchor" id="H2641062116"><span class="h2">Our strategy for patients on methadone maintenance</span><span class="headingEndMark"> — </span>We use the following treatment strategy for patients who are on MMT.</p><p class="headingAnchor" id="H2861757781"><span class="h3">Continue methadone</span><span class="headingEndMark"> — </span>We suggest continuing <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> during acute pain to treat OUD and prevent withdrawal. Confirm the patient's baseline outpatient methadone dose with the patient's opioid treatment program (OTP). Because of its distinctive pharmacokinetic and pharmacodynamic profile, equianalgesic dose conversion guidelines for methadone are notoriously inaccurate. Thus, whenever possible patients should be maintained on their methadone doses without attempts to convert to other agents. (See  <a class="medical medical_review" href="/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia", section on 'How to perform opioid rotation'</a>.)</p><p>If the patient cannot take oral medication, <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> can be given by the intravenous (IV) or subcutaneous route. The parenteral dose should be given as one-half the oral maintenance dose, divided into two to four equal doses through the day [<a href="#rid10">10</a>]. Although it is only legal in the outpatient setting to dispense MMT in a licensed OTP or in a qualified practice, in the inpatient setting, health care providers can legally dispense methadone for addiction treatment as long as the patient is admitted for a reason other than OUD [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H4111522789"><span class="h3">Add nonopioid analgesic strategies</span><span class="headingEndMark"> — </span>Both nonpharmacologic and nonopioid pharmacologic therapy should be maximized before adding further opioid therapy. Non-opioid strategies are often sufficient for treating mild acute pain (eg, after sprains, nonspecific low back pain, dental extraction, headache) and can prevent overuse of opioids. If non-opioid strategies are not adequate, they should be continued while opioids are initiated, thereby reducing the total dose of opioids necessary for pain control. Options include nonopioid analgesics (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and nonsteroidal antiinflammatory drugs), which can be administered intramuscular (IM) or IV in acute severe pain, adjuvant medications (eg, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a>, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, glucocorticoids, gabapentinoids), regional anesthesia techniques, physical measures (eg, cold, heat, or splinting), integrative therapies, and psychosocial or behavioral management strategies. These medications and techniques are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Nonopioid strategies for pain control'</a>.)</p><p><a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> has been shown to reduce hyperalgesia in patients on MMT [<a href="#rid14">14</a>] and does not impact <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> metabolism. The choice of other nonopioid analgesics should be informed by their interactions with methadone. <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">Carbamazepine</a> and <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, for example, induce CYP4503A and could lead to a reduction in methadone levels and pronounced acute opioid withdrawal.</p><p class="headingAnchor" id="H586507341"><span class="h3">Add opioids only as necessary</span><span class="headingEndMark"> — </span>Most laparoscopic and minimally invasive surgery, many soft tissue surgeries, and non-compound and non-comminuted fractures are expected to result in moderate pain that lasts for several days. Moderate pain usually requires short-acting opioids in addition to the patient's baseline opioid and nonopioid multimodal pain control strategies.</p><p>Use of oral and IV opioids for acute pain management for patients on MMT is similar to the use of opioids in patients who take other opioids chronically, and is described in detail separately (see  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Opioids for acute pain'</a>). Issues specific to patients on MMT include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The doses for oral short-acting opioids used for initial pain control in patients who are chronically taking opioids are usually calculated as a fraction of the total daily dose of opioid. However, MME for <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> are notoriously inaccurate. Thus, we start with empiric doses that are higher than those used with opioid-naive patients (eg, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> 20 to 30 mg orally), with dose titration every two to four hours based on pain control  (<a class="graphic graphic_table graphicRef108955" href="/d/graphic/108955.html" rel="external">table 1</a>). For patients with severe pain, we initially control pain rapidly with bolus IV administration of a rapid-onset opioid (eg, <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>, <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>, or <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>) titrated to analgesic requirements, with constant vigilance for respiratory depression, and maintenance of hemodynamic stability, in a closely monitored setting  (<a class="graphic graphic_table graphicRef113048" href="/d/graphic/113048.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Initial pain control'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For inpatients maintained on oral opioids after initial control of pain, short-acting oral opioids  (<a class="graphic graphic_table graphicRef108955" href="/d/graphic/108955.html" rel="external">table 1</a>) should be given on a schedule (every three to four hours, with omission of a dose if sedation or respiratory depression are observed) and not ordered on an as-needed basis. As with all patients on chronic opioids, mixed agonist and antagonist opioid analgesics, such as <a class="drug drug_general" data-topicid="9753" href="/d/drug information/9753.html" rel="external">pentazocine</a>, <a class="drug drug_general" data-topicid="9676" href="/d/drug information/9676.html" rel="external">nalbuphine</a> and <a class="drug drug_general" data-topicid="9179" href="/d/drug information/9179.html" rel="external">butorphanol</a>, should not be administered to patients on <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, as they may displace methadone from the mu receptor and precipitate acute withdrawal.</p><p></p><p class="bulletIndent1">For ambulatory pain management, similar to other patients on chronic opioids, we administer a trial dose before discharging patients from the emergency department or postoperative setting, and provide close follow up in the outpatient setting for dose titration. (See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Oral opioids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who require ongoing IV opioids after initial pain control, either bolus administration or PCA can be used. (See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Ongoing pain control'</a>.)</p><p></p><p class="bulletIndent1">Intermittent IV opioid administration allows bedside assessment of respiratory status and sedation prior to administration of the opioid. However, PCA may be preferable once a stable dose has been established because it provides a sense of control. Control over opioid administration may be particularly valuable in patients with OUD, who often fear and experience undertreatment of pain [<a href="#rid15">15,16</a>]. Setting a cumulative dose limit on the PCA (eg, over a four hour interval) may be considered to decrease the possibility of excessive self-medication with the PCA opioid. (See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Patient-controlled analgesia'</a>.)</p><p></p><p class="headingAnchor" id="H3494131551"><span class="h3">Coordinate with other care providers</span><span class="headingEndMark"> — </span>To prevent destabilization of OUD treatment, it is crucial to communicate with the patient's OTP and/or primary care provider about opioids or other potentially hazardous controlled substances, such as benzodiazepines, to be prescribed at discharge. Concurrent benzodiazepine therapy increases the mortality of patients taking opioids by augmenting opioid-induced ventilatory depression [<a href="#rid17">17-20</a>], and hence must be considered only with great caution. In collaboration with the outpatient providers and with the patient, the inpatient team should establish a plan for tapering off of supplemental opioids or benzodiazepines that may have been started in the hospital. This plan for tapering should be clearly communicated to both the patient and the outpatient prescriber. If the patient's pain requires ongoing short-acting opioids, a clinician outside the <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> program, such as a primary care provider or a pain specialist, may prescribe these while the patient continues once-daily methadone dosing through an OTP. The clinician prescribing these medications for pain should regularly inform the OUD treatment provider of specific medications and doses.</p><p></p><p class="headingAnchor" id="H1376667564"><span class="h1">PATIENTS TAKING BUPRENORPHINE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">Buprenorphine</a> is an opioid that is often used for maintenance pharmacotherapy for OUD and is also increasingly used to treat chronic pain (see  <a class="medical medical_review" href="/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain", section on 'Buprenorphine for chronic pain'</a> and  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Buprenorphine: Opioid agonist'</a>). Buprenorphine is a partial mu-opioid receptor agonist with high affinity for the receptor but low intrinsic activity and is also an antagonist at the kappa-opioid receptor. It is associated with less opioid-induced hyperalgesia than other opioids, causes less euphoria and associated psychologic reward [<a href="#rid21">21,22</a>], and importantly, produces less respiratory depression than other full mu-opioid agonists. Buprenorphine has a ceiling effect for respiratory depression, but not for analgesia, at clinically meaningful doses [<a href="#rid23">23,24</a>].</p><p class="headingAnchor" id="H4164870328"><span class="h2">Whether to continue buprenorphine during pain management</span><span class="headingEndMark"> — </span>We agree with an increasing international consensus that <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> should be continued during an episode of acute pain, whether originally prescribed for chronic pain or for OUD [<a href="#rid25">25-29</a>]. Some experts feel that buprenorphine should be discontinued prior to surgery, however growing evidence suggests that discontinuation is not necessary and is associated with inferior outcomes. Further, the process of tapering and discontinuation of buprenorphine preoperatively adds complexity to the patient management process and increases the risk of return to illicit opioid use.</p><p>Concerns over continuation of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> have centered on the idea that acute pain may be more difficult to control because of competition by buprenorphine with other mu receptor opioids that bind to mu-opioid receptors, due to buprenorphine's high affinity for the mu receptor. Indeed, isolated case reports describe difficulty in controlling acute pain until and unless concurrent buprenorphine is discontinued and treatment is initiated with a full mu opioid agonist or other form of analgesia [<a href="#rid30">30,31</a>]. However, the preponderance of case series, observational studies, and clinical trials demonstrate that effective analgesia for acute pain can be achieved if buprenorphine is continued perioperatively [<a href="#rid32">32-37</a>]. In some cases, patients whose buprenorphine is discontinued prior to surgery may actually require even higher doses of opioids perioperatively, likely because of the opioid deficit created by discontinuation [<a href="#rid35">35,37</a>]. Receptor binding studies suggest that high-potency, full mu-agonist opioids such as <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> and <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> might provide better pain relief than other opioids for patients on buprenorphine. Clinical studies have not confirmed this, but for patients on buprenorphine it is reasonable to turn to these opioids first or to transition to them if pain is not well controlled on other opioids.</p><p>Consensus is growing as well that the optimal perioperative dosing strategy for patients on <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> is to continue on their home dose throughout the perioperative period. Some authors have suggested tapering buprenorphine preoperatively to doses of 12 to 16 mg over two or three days prior to major surgery [<a href="#rid25">25,26</a>], but guidelines now recommend continuing the baseline dose and trials using this approach have demonstrated good pain control [<a href="#rid29">29,38</a>].</p><p class="headingAnchor" id="H975571861"><span class="h2">Our strategy for patients on buprenorphine</span><span class="headingEndMark"> — </span>In general, we manage acute pain for patients who take <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> as we would for other patients who take opioids chronically, including an emphasis on nonopioid pain management strategies. Issues specific to patients who take buprenorphine include the following.</p><p class="headingAnchor" id="H3336248070"><span class="h3">Continue buprenorphine</span><span class="headingEndMark"> — </span>We suggest continuing <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> throughout an episode of acute pain, including postoperative pain, and we administer the patient's usual home doses. One should anticipate that in the presence of buprenorphine, higher than normal doses of any full mu agonist will be required for pain control [<a href="#rid36">36</a>]. (See <a class="local">'Whether to continue buprenorphine during pain management'</a> above.)</p><p>For the vast majority of patients, the transmucosal or sublingual formulation can be administered at the patient's usual home dose. For the rare patient who is unable to tolerate sublingual or buccal <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, intravenous (IV) buprenorphine (without <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a>) can be administered; there is no empirical evidence and minimal clinical experience to guide dosing. For patients who require IV buprenorphine, a reasonable strategy based on bioavailability studies is to reduce the patient's usual daily buprenorphine dose by 50 percent and divide the reduced dose into three equal doses administered intravenously every eight hours. For example, for a patient taking 24/6 mg sublingual buprenorphine/naloxone as an outpatient, clinicians can administer 12 mg of buprenorphine IV total daily, divided into three 4 mg doses every eight hours. Naloxone should <strong>not </strong>be administered in the IV formulation to avoid precipitating withdrawal.</p><p class="headingAnchor" id="H2769887502"><span class="h3">Employ nonopioid analgesic strategies</span><span class="headingEndMark"> — </span>Both nonpharmacologic and nonopioid pharmacologic therapy should be maximized before adding opioid therapy, and should be continued if opioid therapy is used. (See <a class="local">'Our strategy for patients on methadone maintenance'</a> above and  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Nonopioid strategies for pain control'</a>.)</p><p class="headingAnchor" id="H2147151605"><span class="h3">Increase buprenorphine for mild to moderate pain</span><span class="headingEndMark"> — </span>For patients who take <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> for OUD once per day, mild to moderate pain that requires treatment over and above nonopioid analgesics (eg, sprained ankle or limited cellulitis) may be adequately controlled by increasing the patient's buprenorphine dose up to 32 mg/day, divided into doses every six to eight hours. The same approach applies to patients taking concurrent buprenorphine and <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a>. Because naloxone is only minimally bioavailable via the sublingual route, it will not interfere with pain management unless injected. For patients with buprenorphine implants or receiving long-acting depot injections, we do not adjust the buprenorphine dose level and instead proceed to the addition of supplementary full mu agonist opioids if necessary.</p><p class="headingAnchor" id="H3949251575"><span class="h3">Add supplementary opioids for severe or undertreated pain</span><span class="headingEndMark"> — </span>Rather than temporarily increasing the dose of <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> during severe acute pain, a short-acting oral or parenteral full mu opioid agonist should be added as needed, since full mu receptor agonists have greater intrinsic analgesic efficacy. Use of supplementary oral and IV opioids for acute pain management for patients who take buprenorphine is similar to the use of opioids in patients who take other opioids chronically, as described in detail separately (see  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Opioids for acute pain'</a>). Issues specific to patients who take buprenorphine include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The doses for oral short-acting opioids used for initial pain control in patients who are chronically taking opioids are usually calculated as a fraction of the total daily dose of opioid. However, milligram <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> equivalents (MME) cannot be reliably calculated for <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>. Thus, we start with empiric doses that are higher than those used with opioid-naive patients (eg, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> 20 to 30 mg orally), with dose titration every two to four hours based on pain control  (<a class="graphic graphic_table graphicRef108955" href="/d/graphic/108955.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients whose pain is not well controlled with higher doses of full-agonist opioids, we transition patients to a full agonist opioid with a high affinity for the mu opioid receptor (eg <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> or <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>). It is reasonable to start with one of these agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For inpatients who are maintained on oral opioids, after initial control of pain, short-acting oral opioids  (<a class="graphic graphic_table graphicRef108955" href="/d/graphic/108955.html" rel="external">table 1</a>) should be administered on a schedule (every three to four hours, with omission of a dose if sedation or respiratory depression are suspected) and not ordered on an as-needed basis. As for all patients on chronic opioids, mixed agonist and antagonist opioid analgesics, such as <a class="drug drug_general" data-topicid="9753" href="/d/drug information/9753.html" rel="external">pentazocine</a>, <a class="drug drug_general" data-topicid="9676" href="/d/drug information/9676.html" rel="external">nalbuphine</a> and <a class="drug drug_general" data-topicid="9179" href="/d/drug information/9179.html" rel="external">butorphanol</a>, should not be administered to patients on <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, as they may precipitate acute withdrawal.</p><p></p><p class="bulletIndent1">For ambulatory patients, as with other patients on chronic opioids, we administer a trial dose to ensure efficacy before discharging patients from the emergency department or postoperative setting, and provide close follow up in the outpatient setting for dose titration. (See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Oral opioids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with severe pain, we initially control pain rapidly with bolus IV administration of a full mu opioid agonist titrated to analgesic requirements, closely watching for respiratory depression, and maintaining hemodynamic stability in a monitored setting  (<a class="graphic graphic_table graphicRef113048" href="/d/graphic/113048.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Initial pain control'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who require IV opioids after initial control of pain, management is similar to patients who are on <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> as described above. (See <a class="local">'Our strategy for patients on methadone maintenance'</a> above.)</p><p></p><p class="headingAnchor" id="H751705940"><span class="h3">Coordinate care</span><span class="headingEndMark"> — </span>Pain in patients receiving <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> therapy for substance use disorder should be managed in consultation with the patient's addiction medicine team or provider. If the patient will need additional opioids for pain control after discharge from the hospital, it is important to develop a taper plan in collaboration with the outpatient team and with the patient. For patients who take buprenorphine for chronic pain and who require either a change in buprenorphine dose or additional opioids, the patient's chronic opioid prescriber should be involved in determining the duration of treatment and setting a taper plan.</p><p class="headingAnchor" id="H3560806364"><span class="h1">PATIENTS TAKING NALTREXONE</span><span class="headingEndMark"> — </span>Management of acute pain may be particularly challenging in patients who take <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a>, especially for patients who receive monthly injections (XR naltrexone). Naltrexone occupies and blocks activation of mu opioid receptors, and therefore blocks the effectiveness of opioid analgesics for acute pain. However, based on animal studies, it is thought that chronic opioid antagonism with naltrexone increases the density of opioid receptors in the brain, thereby increasing sensitivity to opioid agonists [<a href="#rid39">39</a>]. Thus the risk of side effects (eg, respiratory depression) may be increased if opioid antagonism is overcome or if naltrexone is discontinued during opioid therapy. Opioid antagonism wanes over the course of the month after a dose of XR naltrexone, and case reports describe opioid overdose and death in patients who used opioids at the end of the dosing interval [<a href="#rid40">40</a>]. In addition, reinstitution of naltrexone therapy in patients who have been receiving opioids for pain control can precipitate withdrawal.</p><p>Our approach to treatment of acute pain in patients who take <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Consult the clinician who prescribed <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For elective surgery, discontinue oral <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> at least three days prior to surgery, and XR naltrexone at least one month prior to surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maximize nonopioid methods for perioperative pain control, including <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> and regional anesthesia if possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If opioids are required while <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> is still in effect (ie, within three days of oral naltrexone or within one month of XR naltrexone), opioids should be titrated to effect with monitoring in an intensive care unit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An addiction medicine specialist should be consulted prior to reinstitution of <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> therapy after opioid administration for pain. In most cases, naltrexone should be withheld until the patient has been off opioids for at least seven days.</p><p></p><p class="headingAnchor" id="H1280374144"><span class="h1">PATIENTS WITH OPIOID USE DISORDER IN REMISSION WITHOUT PHARMACOTHERAPY</span><span class="headingEndMark"> — </span>While pharmacotherapy for OUD is associated with reduced mortality and increased rates of recovery, some patients successfully achieve sustained remission from OUD without medication. Treating acute pain with opioids in this population can place them at risk for returning to uncontrolled OUD. Patients in sustained remission from OUD may prefer to use nonpharmacologic or nonopioid pain management because of this risk. Any pain management plan for this population should be made in collaboration with the patient and with an addiction care team.</p><p>As with other patients, nonpharmacologic and nonopioid pain management should be optimized prior to considering opioid analgesia, and regional anesthesia should be considered when possible.</p><p>With severe pain that cannot otherwise be controlled, it is sometimes necessary and appropriate to initiate opioid medications. Opioid tolerance is typically lost within weeks to months after cessation of opioids, so patients in sustained remission have likely lost all opioid tolerance and should be treated with the same doses of opioids as opioid naïve individuals. (See  <a class="medical medical_review" href="/d/html/108806.html" rel="external">"Management of acute pain in opioid naïve adults in the ambulatory setting"</a> and  <a class="medical medical_review" href="/d/html/134254.html" rel="external">"Use of opioids for postoperative pain control"</a>.)</p><p>For mild to moderate pain requiring opioids, we recommend <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> in this population. Though not specifically studied among people with behaviorally treated OUD, the limited euphoria associated with buprenorphine may reduce the risk of return to uncontrolled OUD. As a kappa-opioid antagonist, buprenorphine also reduces the intensity of opioid abstinence syndrome. A starting buprenorphine dose of 2 mg three times daily can be titrated upwards every eight hours in the hospital or every one to three days in the outpatient setting. For more severe pain, full agonist opioids (eg, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> 5 mg) are more appropriate.</p><p>If an outpatient or discharge prescription is necessary, opioids should typically be prescribed for a short (three to five day) course. For pain that is expected to last longer, a clear plan for tapering should be discussed with the patient and their outpatient prescriber. We recommend short durations of prescriptions (five to seven days) with frequent visits to assess impact and titrate dose. Patients with OUD can also benefit from increased psychosocial support and increased engagement with their addiction treatment team both during and for the months following the opioid prescription.</p><p class="headingAnchor" id="H1280222604"><span class="h1">PATIENTS WITH UNTREATED OPIOID USE DISORDER</span><span class="headingEndMark"> — </span>OUD has reached epidemic proportions in the United States, and should be considered in all patients who present for medical treatment. (See  <a class="medical medical_review" href="/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment", section on 'Epidemiology'</a>.)</p><p>Some patients with OUD repeatedly report acute pain in an effort to obtain opioids. Even when this behavior pattern is recognized, a physiologic cause for pain should always be sought.</p><p class="headingAnchor" id="H1180709080"><span class="h2">Screening for OUD</span><span class="headingEndMark"> — </span>OUD is a potentially life-threatening medical condition that responds well to treatment. For patients without a diagnosis of OUD, clinicians who suspect it can use structured assessment tools to confirm the diagnosis. Screening and assessment for OUD is discussed separately. (See  <a class="medical medical_review" href="/d/html/14843.html" rel="external">"Screening for unhealthy use of alcohol and other drugs in primary care"</a> and  <a class="medical medical_review" href="/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a>.)</p><p class="headingAnchor" id="H2449578844"><span class="h2">Treating OUD</span><span class="headingEndMark"> — </span>Intervention for OUD is indicated for patients who screen positive for OUD with a screening tool and/or urine drug testing, with confirmation using Diagnostic and Statistical Manual for Mental Disorders, Fifth Edition (DSM-5) criteria (see  <a class="medical medical_review" href="/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment", section on 'Diagnosis'</a>). Once the acute pain period has subsided, it is critical to discontinue opioids to prevent ongoing misuse, and to engage the patient in compassionate, non-judgmental discussions about their OUD and offer treatment. For patients who are amenable to starting pharmacotherapy for OUD, they can be transitioned from opioids to <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> or <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>. This transition can be made in the hospital setting if a patient remains hospitalized during this phase of treatment, or in the outpatient setting if the patient has been discharged [<a href="#rid41">41-43</a>]. The choice of medication to start for OUD should be a shared decision made with the patient. It should be informed by whether the patient has contraindications to a given medication and what is available with the patient's insurance in the patient's geographic region. Methadone should only be prescribed by clinicians familiar with its use, and with consideration of its unique risk profile and drug interactions. These considerations are discussed separately. (See  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Adverse effects'</a>.)</p><p>In some settings, <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> is more easily available whereas in others, <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> or <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> are easier to arrange after discharge. When a patient is transitioned to buprenorphine or methadone, it is incumbent on the treating team to ensure that the patient has a follow up plan with a waived buprenorphine provider or a licensed OTP for ongoing methadone. If a patient is off of opioids for seven or more days during their hospitalization, they may also consider IM naltrexone to treat their OUD. Emergency departments, hospitals, urgent care clinics, labor and delivery units, and primary care providers can all initiate buprenorphine treatment for OUD if clinicians have received proper training and certification [<a href="#rid41">41-44</a>] (see  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Regulation of methadone in United States'</a> and  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Regulation of buprenorphine in United States'</a>). If the patient is referred elsewhere for treatment, the patient's pain should be managed in collaboration with substance use disorder treatment clinicians and counselors.</p><p class="headingAnchor" id="H558443254"><span class="h2">Outpatient pain management</span><span class="headingEndMark"> — </span>Patients with OUD who have mild pain can often be managed as outpatients, with nonopioid measures for pain control. For moderate pain, prescription of opioids for outpatient treatment should be considered carefully, and if absolutely necessary, a short course (eg, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> 10 mg every six hours for three days) should be prescribed, along with a prescription for <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a>. There is no evidence to suggest that one opioid is safer than another in this situation. Some providers believe that <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a> or oxycodone have a higher potential for misuse, but all short-acting opioids can be inhaled or injected and provide similar euphoric experiences. <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">Buprenorphine</a>, because of its limited euphoric effect, is less likely to be misused, but in patients who are actively using opioids it can precipitate withdrawal and is not recommended.</p><p>A prescription drug monitoring program database should always be checked prior to prescribing opioids in patients with known or suspected OUD. Opioid prescription from another provider that cannot be explained by the patient's clinical history represents a contraindication to prescribing further opioids, or requires workup to determine why the patient requires opioids. (See  <a class="medical medical_review" href="/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management", section on 'Prescription monitoring programs'</a>.)</p><p class="headingAnchor" id="H1704603394"><span class="h2">Inpatient pain management</span><span class="headingEndMark"> — </span>Pain should be treated aggressively to achieve effective analgesia in patients with OUD, with opioid doses titrated upwards rapidly as necessary. The setting of severe acute pain is not the time to attempt opioid weaning and detoxification. On the contrary, undertreated acute pain is a risk factor for chronification of acute pain and persistent opioid use [<a href="#rid45">45-49</a>].</p><p class="headingAnchor" id="H3013934721"><span class="h3">Preventing or treating withdrawal</span><span class="headingEndMark"> — </span>Inpatient pain management may be complicated by untreated withdrawal, as patients do not have access to their usual supply of opioids. It is important to prescribe sufficient opioids to both treat or prevent withdrawal and to sufficiently treat pain. In our experience, this is best accomplished by providing <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> or <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> to minimize symptoms of withdrawal, while adding additional treatment for analgesia. Signs and symptoms of opioid withdrawal are discussed separately. (See  <a class="medical medical_review" href="/d/html/105686.html" rel="external">"Opioid withdrawal: Clinical features, assessment, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p>Before initiating treatment for withdrawal, it is important to discuss with patients their intention to continue pharmacotherapy for OUD after discharge. If they intend to continue medications for OUD after treatment, it is useful to determine which medication they prefer. For patients who would like to take <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> or <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> after discharge it may be preferable to start their preferred medication to treat withdrawal. The factors a patient and provider should consider together when choosing a long term treatment strategy are discussed separately. (See  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management"</a>.)</p><p class="headingAnchor" id="H199751607"><span class="h4">Patients in opioid withdrawal with mild to moderate pain</span><span class="headingEndMark"> — </span>For patients with mild to moderate pain in the hospital (eg, cellulitis) who are in some degree of withdrawal, we suggest administering <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> to manage both withdrawal and pain. We typically administer buprenorphine three times a day, starting at a dose of 4 mg sublingual and titrate upwards as necessary every one to four hours.</p><p class="headingAnchor" id="H2780745750"><span class="h4">Patients in opioid withdrawal with moderate to severe pain</span><span class="headingEndMark"> — </span>For patients with moderate to severe pain who are in opioid withdrawal and who have no preference for <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> treatment after discharge, we suggest administering <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> rather than buprenorphine to treat symptoms of withdrawal and to provide a degree of analgesia, adding short-acting opioids for further pain control. We start methadone at doses of 20 to 30 mg, titrated as described below, and taking into account methadone's adverse effects and drug interactions. (See  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management", section on 'Methadone: Opioid agonist'</a>.)</p><p>We use <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> for patients with moderate to severe pain because it has greater intrinsic analgesic efficacy than <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>. However, if the patient intends to continue treatment for OUD after discharge and prefers buprenorphine for treatment, starting methadone can make it more difficult to transition to buprenorphine after discharge. In this case, prescribers may consider using a different long-acting opioid (eg, oral long-acting <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>) to treat or prevent withdrawal and transitioning to buprenorphine when the patient's pain has improved sufficiently to tolerate 12 hours without opioids.</p><p class="headingAnchor" id="H4225152505"><span class="h4">Patients not in opioid withdrawal on admission or patients with severe pain</span><span class="headingEndMark"> — </span>For patients with OUD who are not in withdrawal or who are in severe pain, the following is a reasonable strategy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administer long-acting opioid to prevent withdrawal, as follows:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Start <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> 20 to 30 mg orally once daily for withdrawal prevention. We do not recommend starting <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> on patients with OUD who are in acute moderate to severe pain and who are not in withdrawal. Patients with OUD who are not in withdrawal may have high systemic opioid levels; buprenorphine may precipitate withdrawal in this setting. (See  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Four hours after the initial dose, if the patient has withdrawal symptoms, administer additional <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> 10 mg orally.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Do not exceed 40 mg of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> on the first day to avoid oversedation and respiratory depression. A steady state of methadone takes 4.5 days to achieve, so slow titration is critical.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients should be supported in enrolling in long term pharmacotherapy to treat OUD and to reduce the risk of death from overdose after discharge.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients intending to enter <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance therapy (MMT), methadone should be titrated up by 10 mg each day on subsequent days to eliminate withdrawal symptoms and reduce cravings. At a daily dose of 60 mg, we recommend pausing for five days to achieve a steady state serum level. After that, the dose can be increased by 10 mg each week in collaboration with the patient's accepting OTP. This titration is more rapid than recommended in the outpatient setting, but is considered appropriate in the inpatient setting because of the higher degree of monitoring and the urgency to prevent or treat withdrawal. (See  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the patient does not intend to continue MMT as an outpatient, their dose should be titrated to eliminate withdrawal (typically achieved by daily doses of 40 mg), but should not be titrated to the high levels required to eliminate cravings (typically 80 mg or higher). Because the patient will be discharged without <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, the severity of withdrawal on discharge can be somewhat limited by keeping the dose 40 mg or lower in the hospital and titrating down to 20 mg on the day of discharge.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients who prefer to take <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> for medication-assisted treatment after discharge can be transitioned to buprenorphine with the help of an addiction specialist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnose and treat the pain</strong> — After administration of medication to prevent withdrawal, diagnosis and treatment of acute pain in patients with OUD is similar to treatment for other patients who chronically use <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, or other opioids. A multimodal approach should be used, starting with nonpharmacologic and nonopioid pharmacologic strategies, with oral or parenteral opioids added as necessary. (See  <a class="medical medical_review" href="/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Creating a plan for treatment'</a>.)</p><p></p><p class="bulletIndent1">For patients with untreated OUD, the doses of opioids they use on a daily basis may be difficult or impossible to determine. Thus, if opioids are required for acute pain control an empiric starting dose may be required, followed by rapid titration and observation. Increased tolerance to opioids and therefore higher required doses can be expected. (See <a class="local">'Our strategy for patients on methadone maintenance'</a> above.)</p><p></p><p class="headingAnchor" id="H1961066342"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113643.html" rel="external">"Society guideline links: Opioid use disorder and withdrawal"</a> and  <a class="medical medical_society_guidelines" href="/d/html/118304.html" rel="external">"Society guideline links: Acute pain management"</a>.)</p><p class="headingAnchor" id="H3086787483"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute pain management in patients treated with opioid use disorder (OUD) frequently requires coordination with substance use disorder treatment specialists. (See <a class="local">'Coordinate with other care providers'</a> above and <a class="local">'Coordinate care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The general principles of acute pain management for patients who receive <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> or <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> are similar to the principles used for patients who take other opioids chronically: continue the baseline opioid, maximize nonopioid and nonpharmacologic analgesic strategies, and administer supplemental opioid only if necessary. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For inpatients with severe pain requiring IV opioids, we seek to control pain rapidly with IV boluses in a closely monitored setting. For ongoing pain control with IV opioids, either bolus administration or patient-controlled analgesia (PCA) can be used. (See  <a class="medical medical_review" href="/d/html/134254.html" rel="external">"Use of opioids for postoperative pain control", section on 'Treating pain in the postanesthesia care unit (PACU)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who take </strong><a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who take <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, we suggest continuing maintenance methadone during an episode of acute pain (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients who cannot take oral medications, methadone can be administered by the intravenous (IV) or subcutaneous routes, at a dose one-half the oral maintenance dose divided into two to four equal doses throughout the day. (See <a class="local">'Patients on methadone maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose conversions between <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> and other opioids are problematic. Thus, for patients on methadone who require oral opioids for initial pain control, we start with empiric doses of short-acting oral opioids at doses higher than would be used for opioid naïve patients (eg, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> 20 to 30 mg orally), with dose titration every four hours based on pain control. More rapid titration of IV opioids is appropriate for more severe pain. (See <a class="local">'Add opioids only as necessary'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who take </strong><a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who take <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> for either OUD or chronic pain, we suggest continuing buprenorphine during an episode of acute pain (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>), and we continue the patient's home dose. (See <a class="local">'Whether to continue buprenorphine during pain management'</a> above and <a class="local">'Continue buprenorphine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If opioids are required for mild acute pain in patients who take <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a>, after maximizing nonopioid analgesic strategies, the dose of buprenorphine can be increased up to 32 mg per day, divided into doses every six to eight hours. For moderate to severe pain, other opioids can be added to the regimen, similar to patients on <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>. (See <a class="local">'Add supplementary opioids for severe or undertreated pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose conversions between <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> and other opioids are problematic. Thus, for patients on buprenorphine who require oral opioids for initial pain control, we start with empiric doses of short-acting oral opioids at doses higher than would be used for opioid naïve patients (eg, <a class="drug drug_general" data-topicid="9729" href="/d/drug information/9729.html" rel="external">oxycodone</a> 20 to 30 mg orally), with dose titration every four hours based on pain control. More rapid titration of IV opioids is appropriate for more severe pain. (See <a class="local">'Add supplementary opioids for severe or undertreated pain'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who take </strong><a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a> – Naltrexone blocks the mu-opioid receptor, rendering the use of opioids for acute pain management problematic. Oral naltrexone should be discontinued at least three days prior to elective procedures. Naltrexone XR should be held for 30 days prior to elective procedures. If opioids are required while naltrexone is still in effect, they should be titrated to effect with close ventilatory monitoring. (See <a class="local">'Patients taking naltrexone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with untreated OUD</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with untreated OUD, outpatient opioids should be considered only with great caution and after exhaustion of alternatives. If absolutely necessary, a short course (ie, ≤3 days) should be prescribed along with a prescription of <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> for treatment of overdose and in collaboration with the outpatient prescribing team. (See <a class="local">'Outpatient pain management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A key goal for pain management in inpatients with untreated OUD is prevention or mitigation of opioid withdrawal.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who are in some degree of opioid withdrawal and have mild pain, we suggest administering <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> to manage both pain and withdrawal (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patients in opioid withdrawal with mild to moderate pain'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with moderate to severe pain who are in opioid withdrawal and who have no preference for <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> treatment after discharge, we suggest administering <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> rather than buprenorphine to treat symptoms of withdrawal and to provide a degree of analgesia, adding short-acting opioids for further pain control (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patients in opioid withdrawal with moderate to severe pain'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who are not in opioid withdrawal or who have severe pain, we suggest administering <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> to prevent withdrawal (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). After administration of methadone to prevent withdrawal, treatment of pain is similar to treatment with other patients who chronically use opioids. (See <a class="local">'Inpatient pain management'</a> above.)</p><p></p><p class="headingAnchor" id="H1406112945"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Diana Coffa, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Quinlan J, Cox F. Acute pain management in patients with drug dependence syndrome. Pain Rep 2017; 2:e611.</a></li><li><a class="nounderline abstract_t">Athanasos P, Smith CS, White JM, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain 2006; 120:267.</a></li><li><a class="nounderline abstract_t">Doverty M, Somogyi AA, White JM, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 2001; 93:155.</a></li><li><a class="nounderline abstract_t">Hay JL, White JM, Bochner F, Somogyi AA. Antinociceptive effects of high-dose remifentanil in male methadone-maintained patients. Eur J Pain 2008; 12:926.</a></li><li><a class="nounderline abstract_t">Chan FJ, Schwartz AM, Wong J, et al. Use of Chronic Methadone Before Total Knee Arthroplasty. J Arthroplasty 2017; 32:2105.</a></li><li><a class="nounderline abstract_t">Hansen LE, Stone GL, Matson CA, et al. Total Joint Arthroplasty in Patients Taking Methadone or Buprenorphine/Naloxone Preoperatively for Prior Heroin Addiction: A Prospective Matched Cohort Study. J Arthroplasty 2016; 31:1698.</a></li><li><a class="nounderline abstract_t">Meyer M, Wagner K, Benvenuto A, et al. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol 2007; 110:261.</a></li><li><a class="nounderline abstract_t">Rowley D, McLean S, O'Gorman A, et al. Review of cancer pain management in patients receiving maintenance methadone therapy. Am J Hosp Palliat Care 2011; 28:183.</a></li><li><a class="nounderline abstract_t">Hines S, Theodorou S, Williamson A, et al. Management of acute pain in methadone maintenance therapy in-patients. Drug Alcohol Rev 2008; 27:519.</a></li><li><a class="nounderline abstract_t">Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006; 144:127.</a></li><li><a class="nounderline abstract_t">Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. Anesthesiology 2004; 101:212.</a></li><li><a class="nounderline abstract_t">Taveros MC, Chuang EJ. Pain management strategies for patients on methadone maintenance therapy: a systematic review of the literature. BMJ Support Palliat Care 2017; 7:383.</a></li><li class="breakAll">Title 21 Code of Federal Regulations 1206.07 (c) 21 CFR 1306.07(c).</li><li><a class="nounderline abstract_t">Compton P, Kehoe P, Sinha K, et al. Gabapentin improves cold-pressor pain responses in methadone-maintained patients. Drug Alcohol Depend 2010; 109:213.</a></li><li><a class="nounderline abstract_t">Merrill JO, Rhodes LA, Deyo RA, et al. Mutual mistrust in the medical care of drug users: the keys to the "narc" cabinet. J Gen Intern Med 2002; 17:327.</a></li><li><a class="nounderline abstract_t">Karasz A, Zallman L, Berg K, et al. The experience of chronic severe pain in patients undergoing methadone maintenance treatment. J Pain Symptom Manage 2004; 28:517.</a></li><li><a class="nounderline abstract_t">Gaither JR, Goulet JL, Becker WC, et al. The Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality. J Gen Intern Med 2016; 31:492.</a></li><li><a class="nounderline abstract_t">Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 2017; 356:j760.</a></li><li><a class="nounderline abstract_t">Park TW, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ 2015; 350:h2698.</a></li><li><a class="nounderline abstract_t">Dowell D, Ragan KR, Jones CM, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022; 71:1.</a></li><li><a class="nounderline abstract_t">Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35:501.</a></li><li><a class="nounderline abstract_t">Fudala PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47:525.</a></li><li><a class="nounderline abstract_t">Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 2010; 10:428.</a></li><li><a class="nounderline abstract_t">Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008; 8:287.</a></li><li><a class="nounderline abstract_t">Quaye AN, Zhang Y. Perioperative Management of Buprenorphine: Solving the Conundrum. Pain Med 2019; 20:1395.</a></li><li><a class="nounderline abstract_t">Lembke A, Ottestad E, Schmiesing C. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period. Pain Med 2019; 20:425.</a></li><li><a class="nounderline abstract_t">Goel A, Azargive S, Weissman JS, et al. Perioperative Pain and Addiction Interdisciplinary Network (PAIN) clinical practice advisory for perioperative management of buprenorphine: results of a modified Delphi process. Br J Anaesth 2019; 123:e333.</a></li><li><a class="nounderline abstract_t">Haber LA, DeFries T, Martin M. Things We Do for No Reason™: Discontinuing Buprenorphine When Treating Acute Pain. J Hosp Med 2019; 14:633.</a></li><li><a class="nounderline abstract_t">Kohan L, Potru S, Barreveld AM, et al. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med 2021; 46:840.</a></li><li><a class="nounderline abstract_t">Huang A, Katznelson R, de Perrot M, Clarke H. Perioperative management of a patient undergoing Clagett window closure stabilized on Suboxone® for chronic pain: a case report. Can J Anaesth 2014; 61:826.</a></li><li><a class="nounderline abstract_t">Brummett CM, Trivedi KA, Dubovoy AV, Berland DW. Dexmedetomidine as a novel therapeutic for postoperative pain in a patient treated with buprenorphine. J Opioid Manag 2009; 5:175.</a></li><li><a class="nounderline abstract_t">Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage 2006; 32:175.</a></li><li><a class="nounderline abstract_t">Oifa S, Sydoruk T, White I, et al. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery. Clin Ther 2009; 31:527.</a></li><li><a class="nounderline abstract_t">Vilkins AL, Bagley SM, Hahn KA, et al. Comparison of Post-Cesarean Section Opioid Analgesic Requirements in Women With Opioid Use Disorder Treated With Methadone or Buprenorphine. J Addict Med 2017; 11:397.</a></li><li><a class="nounderline abstract_t">Macintyre PE, Russell RA, Usher KA, et al. Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy. Anaesth Intensive Care 2013; 41:222.</a></li><li><a class="nounderline abstract_t">Martin YN, Pearson ACS, Tranchida JR, et al. Implications of uninterrupted preoperative transdermal buprenorphine use on postoperative pain management. Reg Anesth Pain Med 2019; 44:342.</a></li><li><a class="nounderline abstract_t">Quaye A, Potter K, Roth S, et al. Perioperative Continuation of Buprenorphine at Low-Moderate Doses Was Associated with Lower Postoperative Pain Scores and Decreased Outpatient Opioid Dispensing Compared with Buprenorphine Discontinuation. Pain Med 2020; 21:1955.</a></li><li><a class="nounderline abstract_t">Silva MJ, Rubinstein A. Continuous Perioperative Sublingual Buprenorphine. J Pain Palliat Care Pharmacother 2016; 30:289.</a></li><li><a class="nounderline abstract_t">Curatolo C, Trinh M. Challenges in the perioperative management of the patient receiving extended-release naltrexone. A A Case Rep 2014; 3:142.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021897s015lbl.pdf.</li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol (TIP) 63: Medications for Opioid Use Disorder. Rockville, MD: 2018.</li><li><a class="nounderline abstract_t">D'Onofrio G, Chawarski MC, O'Connor PG, et al. Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention. J Gen Intern Med 2017; 32:660.</a></li><li><a class="nounderline abstract_t">Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med 2014; 174:1369.</a></li><li><a class="nounderline abstract_t">Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320.</a></li><li><a class="nounderline abstract_t">Gottschalk A, Ochroch EA. Clinical and demographic characteristics of patients with chronic pain after major thoracotomy. Clin J Pain 2008; 24:708.</a></li><li><a class="nounderline abstract_t">Puolakka PA, Rorarius MG, Roviola M, et al. Persistent pain following knee arthroplasty. Eur J Anaesthesiol 2010; 27:455.</a></li><li><a class="nounderline abstract_t">Wang L, Guyatt GH, Kennedy SA, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ 2016; 188:E352.</a></li><li><a class="nounderline abstract_t">Poleshuck EL, Katz J, Andrus CH, et al. Risk factors for chronic pain following breast cancer surgery: a prospective study. J Pain 2006; 7:626.</a></li><li><a class="nounderline abstract_t">Fletcher D, Stamer UM, Pogatzki-Zahn E, et al. Chronic postsurgical pain in Europe: An observational study. Eur J Anaesthesiol 2015; 32:725.</a></li></ol></div><div id="topicVersionRevision">Topic 121628 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29392226" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Acute pain management in patients with drug dependence syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16427197" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11427327" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18262451" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antinociceptive effects of high-dose remifentanil in male methadone-maintained patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28343821" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Use of Chronic Methadone Before Total Knee Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26899477" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Total Joint Arthroplasty in Patients Taking Methadone or Buprenorphine/Naloxone Preoperatively for Prior Heroin Addiction: A Prospective Matched Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17666599" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20826493" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Review of cancer pain management in patients receiving maintenance methadone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18696299" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Management of acute pain in methadone maintenance therapy in-patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418412" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220793" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Perioperative management of acute pain in the opioid-dependent patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27566722" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pain management strategies for patients on methadone maintenance therapy: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27566722" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pain management strategies for patients on methadone maintenance therapy: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20163921" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gabapentin improves cold-pressor pain responses in methadone-maintained patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12047728" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mutual mistrust in the medical care of drug users: the keys to the "narc" cabinet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15504628" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The experience of chronic severe pain in patients undergoing methadone maintenance treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26847447" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The Association Between Receipt of Guideline-Concordant Long-Term Opioid Therapy and All-Cause Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28292769" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26063215" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36327391" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/215096" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2328561" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20492579" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Current knowledge of buprenorphine and its unique pharmacological profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18503626" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30500943" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Perioperative Management of Buprenorphine: Solving the Conundrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29452378" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31153631" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Perioperative Pain and Addiction Interdisciplinary Network (PAIN) clinical practice advisory for perioperative management of buprenorphine: results of a modified Delphi process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31433765" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Things We Do for No Reason™: Discontinuing Buprenorphine When Treating Acute Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34385292" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24985936" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Perioperative management of a patient undergoing Clagett window closure stabilized on Suboxone®for chronic pain: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19662927" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Dexmedetomidine as a novel therapeutic for postoperative pain in a patient treated with buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877185" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19393843" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28727661" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comparison of Post-Cesarean Section Opioid Analgesic Requirements in Women With Opioid Use Disorder Treated With Methadone or Buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23530789" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30635504" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Implications of uninterrupted preoperative transdermal buprenorphine use on postoperative pain management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32167541" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Perioperative Continuation of Buprenorphine at Low-Moderate Doses Was Associated with Lower Postoperative Pain Scores and Decreased Outpatient Opioid Dispensing Compared with Buprenorphine Discontinuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27736284" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Continuous Perioperative Sublingual Buprenorphine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25612099" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Challenges in the perioperative management of the patient receiving extended-release naltrexone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25612099" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Challenges in the perioperative management of the patient receiving extended-release naltrexone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25612099" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Challenges in the perioperative management of the patient receiving extended-release naltrexone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28194688" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25090173" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21142534" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Neonatal abstinence syndrome after methadone or buprenorphine exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18806536" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical and demographic characteristics of patients with chronic pain after major thoracotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20299989" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Persistent pain following knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27402075" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16942948" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Risk factors for chronic pain following breast cancer surgery: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26241763" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chronic postsurgical pain in Europe: An observational study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
